Pharmacotherapeutic Advances in Cardiac Resuscitation: A Review of the Advanced Cardiac Life Support (ACLS) 2000 Guidelines and Their Impact on Pharmacy Practice
Restricted accessResearch articleFirst published online February, 2001
Pharmacotherapeutic Advances in Cardiac Resuscitation: A Review of the Advanced Cardiac Life Support (ACLS) 2000 Guidelines and Their Impact on Pharmacy Practice
The treatment of sudden cardiac death is a challenging area of pharmacotherapy. Despite decades of medication use, outcomes from the treatment of cardiac arrest remain poor. Recent advances in the treatment of cardiac arrest have been incorporated into the American Heart Association’s Advanced Cardiac Life Support 2000 guidelines. A summary and review of these guidelines are presented. Included in the changes to the cardiac arrest treatment guidelines are new medications (amiodarone and vasopressin), new approaches to using medications and the evidence to support these changes. The implications of instituting these new guidelines and strategies for the implementation of the new paradigm are discussed.
AHA Standards for cardiopulmonary resuscitation and emergency cardiac care. JAMA.1974; 227:833-868.
2.
Nichol G, Detsky AS, Stiell IGet al. Effectiveness of emergency medical services for victims of out-of-hospital cardiac arrest: A meta-analysis. Ann Emerg Med. 1996 Jun; 27(6):700-710.
3.
Lombardi G, Gallagher E, Gennis P.Outcome of out-of-hospital cardiac arrest in New York City: The pre-hospital arrest survival evaluation (PHASE) study. JAMA. 1994 Mar 2; 271(9):678-683.
4.
Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2000; 102(8 suppl):I1-I384.
5.
Weaver WD, Fahrenbruch CE, Johnson DDet al. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation. 1990; 82(6):2027-2034.
6.
Vachiery JL, Reuse C, Blecic Set al. Bretylium tosylate versus lidocaine in experimental cardiac arrest. Am J Emerg Med. 1990; 8(6):492-495.
7.
van Walraven C, Stiell IG, Wells GAet al. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC Study Group. Ann Emerg Med. 1998; 32(5):544-553.
8.
Herlitz J, Ekstrom L, Wennerblom Bet al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival?Resuscitation. 1997; 33(3): 199-205.
9.
Chow MS, Kluger J, Lawrence R, Fieldman A.The effect of lidocaine and bretylium on the defibrillation threshold during cardiac arrest and cardiopulmonary resuscitation. Proc Soc Exp Biol Med. 1986; 182(1):63-67.
10.
Lindner KH, Ahnefeld FW, Bowdler IM. Comparison of different doses of epinephrine on myocardial perfusion and resuscitation success during cardiopulmonary resuscitation in a pig model. Am J Emerg Med. 1991; 9(1):27-31.
11.
Brown CG, Martin DR, Pepe PEet al. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. N Eng J Med. 1992; 327:1051-1055.
12.
Stiell IG, Hebert PC, Weitzman BNet al. High-dose epinephrine in adult cardiac arrest. N Engl J Med. 1992; 327(15):1045-1050.
13.
Callaham M, Madsen CD, Barton CWet al. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. JAMA. 1992; 268(19):2667-2672.
14.
Nowak RM, Bodnar TJ, Dronen S, et al. Bretylium tosylate as initial treatment for cardiopulmonary arrest: randomized comparison with placebo. Ann Emerg Med. 1981; 10(8):404-407.
15.
Nanas JN, Mason JW. Pharmcokinetics and regional electrophysiological effects of intracoronary amiodarone administration. Circulation. 1995; 91(2):451-461.
16.
Du XJ, Elser MD, Dart AM. Sympatholytic action of amiodarone in the rat heart. Circulation. 1995; 91(2):462-470.
17.
Haikerwal D, Dart AMLittle PJet al. Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport. J Pharmacol Exp Ther. 1999; 288:834-837.
Chen BP, White CM, Fan Cet al. The effect of amiodarone on the ventricular fibrillation threshold. Pharmacotherapy. 1999; 19(7):832-837.
20.
Kudenchuk PJ, Cobb LA, Copass MKet al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Eng J Med. 1999; 341:871-878.
21.
Williams ML, Woelfel A, Cascio WEet al. Intravenous amiodarone during prolonged resuscitation from cardiac arrest. Ann Intern Med. 1989; 110(10):839-842.
22.
Chugh SS, Lurie KG, Lindner KH. Pressor with promise: Using vasopressin in cardiopulmonary arrest. Circulation. 1997; 96:2453-2454.
23.
Lindner KH, Prengel AW, Strohmenger HUet al. Vasopressin administration in refractory cardiac arrest. Ann Int Med. 1996; 124:1061-1064.
24.
Morris DC, Dereczyk BE, Grzybowski Met al. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med. 1997; 4(9):878-883.
25.
Lindner KH, Dirks B, Strohmenger HUet al. Randomized comparison of epinephrine and vasopressin in patients in out-of-hospital ventricular tachycardia. Lancet. 1997; 349:535-537.
26.
Wenzel V, Ewy GA, Lindner KH. Vasopressin and endothelin during cardiopulmonary resuscitation. Crit Care Med. 2000; 28(11 Suppl):N233-N235.
27.
Warren RJ, Stedman RJ, Shami EGet al. Effect of polysorbate 80 on the solubility and in vivoavailability of 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride (SK&F 33134-A) by NMR spectroscopy. J Pharm Sci. 1970; 59(9):1357-1358.
28.
Ravin LJ, Shami EG, Rattie ES. Micelle formation and its relationship to solubility behavior of 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride. J Pharm Sci. 1975; 64(11):1830-1833.
29.
Hasegawa GR and Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectible drugs. Am J Hosp Pharm.1984; 41:1379-1380.
30.
Campbell S, Nolan PE Jr, Bliss Met al. Stability of amiodarone hydrochloride in admixtures with other injectible drugs. Am J Hosp Pharm.1986; 43:917-921.
31.
Benedict MKet al. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm. 1988; 45:1117-1118.
32.
Strozyk WR, Williamson R, Thompson D.Incompatibility of amiodarone hydrochloride and evacuated glass bottles. Am J Health Syst Pharm. 1996; 15;53(2):184.
33.
Peters PG, Hayball PJ. A comparative analysis of the loss of amiodarone from small and large volume PVC and non-PVC infusion systems. Anaesth Intensive Care. 1990; 18(2):241-245.
34.
Blake TL and Reasor MJ. Acute pulmonary inflammation in hamsters following intratracheal administration of amiodarone. Inflammation. 1995; 19(1):55-56.
35.
Blake TL and Reasor MJ. Pulmonary responses to amiodarone in hamsters: comparison of intratracheal and oral administrations. Toxicol Appl Pharmacol. 1995; 131(2):325-331.
36.
Grimm W, Steder U, Menz Vet al. Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events. Clin Cardiol. 1997; 20(2):107-110.
37.
Wenzel V, Lindner KH, Krismer ACet al. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation. 1999; 99:1379-1384.
38.
Achleitner U, Wenzel V, Strohmenger HUet al. The effects of repeated doses of vasopressin or epinephrine on ventricular fibrillation in a porcine model of prolonged cardiopulmonary resuscitation. Anesth Analg. 2000; 90(5):1067-1075.
39.
Mulligan KA, McKnite SH, Lindner KHet al. Synergistic effects of vasopressin plus epinephrine during cardiopulmonary resuscitation. Resuscitation. 1997; 35(3):265-271.
40.
Wenzel V, Lindner KH, Augenstein Set al. Vasopressin combined with epinephrine decreases cerebral perfusion compared with vasopressin alone during cardiopulmonary resuscitation in pigs. Stroke. 1998; 29:1462-1468.
41.
Wenzel V, Lindner KH, Mayer Het al. Vasopressin combined with nitroglycerin increases endocardial perfusion during cardiopulmonary resuscitation in pigs. Resuscitation. 1998; 38(1):13-17.
